Pharmacovigilance data flow shows ~1,233 global and ~2,133 Germany-reported post-vaccination deaths in the first two months; applying a 10×–30× underreporting multiplier yields 20,000–60,000 potential fatalities, contrasting with regulatory causality reviews finding only ~150–300 linked cases. Trial oversight failures at Ventavia led to a temporary recruitment stop.

Annual revenue topped $62.6 B with $7.8 B profit (>12% margin), 2026 revenue guidance of $59.5–62.5 B with ~4% ex-COVID growth, Q1 revenue up ~0.9% to $13.83 B and EPS down ~19.6% to $0.74, full-year EPS guided at $2.80–3.00 with further modest declines into 2027, supported by a >100-candidate pipeline, obesity approvals targeted from 2028, and the $43 B Seagen acquisition.

Comirnaty’s emergency approval bypassed full carcinogenicity and reproductive toxicity studies, prompting German inquiry reviews of 2,133 reported post-vaccine deaths and disputed underreporting multipliers that project tens of thousands of fatalities versus official causal links of roughly 74–127. US and EU regulators maintain that rare adverse events are identified and benefits exceed risks. Meanwhile, Pfizer’s 2025 growth is driven by international Prevnar sales and Seagen-acquired ADCs, even as US COVID-19 vaccine uptake falls under tighter guidelines and a 2026 patent cliff threatens $1.5 billion in exclusivity losses.

Safety fears fueled by veteran toxicologist testimony alleging skipped carcinogenicity and reproductive tests and underreported vaccine deaths collide with official assurances and real-world reviews affirming no mass harm and clear net benefits in high-risk groups. Investor sentiment on Pfizer’s stock remains cautious to neutral, with price targets implying modest upside, valuations trading below long-term averages, underperformance versus the S&P, and hopes pinned on an uncertain pipeline catalyst.